The top Democrat on the House Energy and Commerce Committee has asked a government watchdog to review the TrumpRx drug website, STAT and Bloomberg Government report.

Representative Frank Pallone Jr. of New Jersey sent the request to the Government Accountability Office in a letter dated October 27. He asked the agency to find out whether the site has saved Americans any money.

TrumpRx.gov launched in February. It does not sell or dispense drugs. Instead it directs people to coupons or links for discounts, STAT reports. The White House says the site has helped Americans save $700 million.

Pallone wrote that the administration has failed to "disclose key information" needed to judge whether the site offers "any meaningful financial benefit." STAT reports he pointed to the lack of details on pricing deals the White House reached with more than two dozen drugmakers.

According to the letter, Democrats asked the president for those agreements in March, and he has not provided them. Two heavily redacted deals have come out through public records lawsuits.

The letter asks the GAO to look at how many purchases have gone through the site, how many people used it and whether they had insurance. It also asks which drugs are bought most, whether some are cheaper elsewhere and how the White House reached its $700 million figure. It also asks whether the government is tracking patient safety.

Bloomberg Government reports the request is the latest push by congressional Democrats for more details on the drug deals. Pallone could take over the committee if Democrats win the House majority in next week's elections.

What we know: Pallone has formally asked the GAO to review TrumpRx and the White House's $700 million savings claim.
What we don't: Whether the GAO will take up the review, and how the White House will respond.